Skip to main content
SpringerLink
Log in

Inflammation and Lung Cancer: The Relationship to Chronic Obstructive Pulmonary Disease

  • Chapter
  • First Online:
Inflammation and Lung Cancer

Abstract

Numerous epidemiological studies have consistently linked the presence of chronic obstructive pulmonary disease (COPD) with increased lung cancer incidence even after correcting for cigarette smoke consumption. The mechanistic explanations for this epidemiologic link remain poorly understood as the two disease processes are seemingly polar opposites. However, there are key shared pathologic mechanisms that may link COPD and lung cancer, and inflammation is one of these factors, with the progression of both diseases substantially modified by the presence of chronic inflammatory cell infiltrates. Here, we review the most likely means by which cigarette smoke-induced inflammation would promote the development of lung cancer in COPD subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Google Scholar 

  2. Youlden DR, Cramb SM, Baade PD (2008) The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 3:819–831

    Google Scholar 

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Google Scholar 

  4. Hoyert DL XJ (2012) Deaths: preliminary data for 2011. Natl Vital Stat Rep 61:1–65

    Google Scholar 

  5. Skillrud DM, Offord KP, Miller RD (1986) Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 105:503–507

    Google Scholar 

  6. Tockman MS, Anthonisen NR, Wright EC, Donithan MG (1987) Airways obstruction and the risk for lung cancer. Ann Intern Med 106:512–518

    Google Scholar 

  7. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD (2005) Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 60:570–575

    Google Scholar 

  8. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 163:1256–1276

    Google Scholar 

  9. Shapiro SD, Ingenito EP (2005) The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol 32:367–372

    Google Scholar 

  10. Shapiro SD (1995) The pathogenesis of emphysema: the elastase: antielastase hypothesis 30 years later. Proc Assoc Am Physicians 107:346–352

    Google Scholar 

  11. Heidelberger KP (1976) Alpha-1-antitrypsin deficiency: a review; 1963–1975. Ann Clin Lab Sci 6:110–117

    Google Scholar 

  12. Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M (1965) Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health 11:50–58

    Google Scholar 

  13. Tuder RM, Petrache I (2012) Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 122:2749–2755

    Google Scholar 

  14. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Google Scholar 

  15. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8:381–385

    Google Scholar 

  16. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr (1989) Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis 140:S49–S55

    Google Scholar 

  17. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P (1990) Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis 141:613–617

    Google Scholar 

  18. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD (2009) COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 34:380–386

    Google Scholar 

  19. Sin DD, Anthonisen NR, Soriano JB, Agusti AG (2006) Mortality in COPD: role of comorbidities. Eur Respir J 28:1245–1257.

    Google Scholar 

  20. de Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, Pueyo JC, Villanueva A, Lozano MD, Montes U et al (2007) Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 132:1932–1938

    Google Scholar 

  21. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, Leader JK, Siegfried JM, Shapiro SD et al (2008) Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 178:738–744

    Google Scholar 

  22. Zulueta JJ, Wisnivesky JP, Henschke CI, Yip R, Farooqi AO, McCauley DI, Chen M, Libby DM, Smith JP, Pasmantier MW et al (2012) Emphysema scores predict death from COPD and lung cancer. Chest 141:1216–1223

    Google Scholar 

  23. Li Y, Swensen SJ, Karabekmez LG, Marks RS, Stoddard SM, Jiang R, Worra JB, Zhang F, Midthun DE, de Andrade M et al (2011) Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. Cancer Prev Res (Phila) 4:43–50

    Google Scholar 

  24. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR (2010) Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest 138:1295–1302

    Google Scholar 

  25. Wilson DO, Leader JK, Fuhrman CR, Reilly JJ, Sciurba FC, Weissfeld JL (2011) Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the Pittsburgh lung screening study. J Thorac Oncol 6:1200–1205

    Google Scholar 

  26. Reedy J (1975) Galen on cancer and related diseases. Clio Med 10:227–238

    Google Scholar 

  27. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? The Lancet 357:539–545

    Google Scholar 

  28. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867

    Google Scholar 

  29. Karimi R, Tornling G, Grunewald J, Eklund A, Skold CM (2012) Cell recovery in bronchoalveolar lavage fluid in smokers is dependent on cumulative smoking history. PLoS ONE 7:e34232

    Google Scholar 

  30. Merchant RK, Schwartz DA, Helmers RA, Dayton CS, Hunninghake GW (1992) Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis 146:448–453

    Google Scholar 

  31. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653

    Google Scholar 

  32. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE et al (2004) An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 1:e8

    Google Scholar 

  33. Maeno T, Houghton AM, Quintero PA, Grumelli S, Owen CA, Shapiro SD (2007) CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol 178:8090–8096

    Google Scholar 

  34. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD (1997) Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277:2002–2004

    Google Scholar 

  35. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI (1997) Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 155:1770–1776

    Google Scholar 

  36. Di Stefano A, Caramori G, Capelli A, Gnemmi I, Ricciardolo FL, Oates T, Donner CF, Chung KF, Barnes PJ, Adcock IM (2004) STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 24:78–85

    Google Scholar 

  37. Kuhn C, Yu SY, Chraplyvy M, Linder HE, Senior RM (1976) The induction of emphysema with elastase. II. Changes in connective tissue. Lab Invest 34:372–380

    Google Scholar 

  38. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey BG, O'Connor TP, Crystal RG (2009) Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 183:2867–2883

    Google Scholar 

  39. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15

    Google Scholar 

  40. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P et al (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116:2777–2790

    Google Scholar 

  41. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465

    Google Scholar 

  42. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37

    Google Scholar 

  43. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555

    Google Scholar 

  44. Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71:2411–2416

    Google Scholar 

  45. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447–458

    Google Scholar 

  46. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A et al (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25:2105–2112

    Google Scholar 

  47. Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C, Mouroux J, Hofman P (2012) Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 118:1726–1737

    Google Scholar 

  48. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123–1132

    Google Scholar 

  49. Gaffen SL (2009) The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 11:365–370

    Google Scholar 

  50. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556–567

    Google Scholar 

  51. Chen K, Pociask DA, McAleer JP, Chan YR, Alcorn JF, Kreindler JL, Keyser MR, Shapiro SD, Houghton AM, Kolls JK et al (2011) IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS ONE 6:e20333

    Google Scholar 

  52. Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, Seryshev A, Zhang Y, Hilsenbeck S, Chang SH, Dong C et al (2012) Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med 4:117ra119.

    Google Scholar 

  53. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457–1464

    Google Scholar 

  54. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787–798

    Google Scholar 

  55. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV et al (2013) An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19:1114–1123

    Google Scholar 

  56. Mutze S, Hebling U, Stremmel W, Wang J, Arnhold J, Pantopoulos K, Mueller S (2003) Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1. J Biol Chem 278:40542–40549

    Google Scholar 

  57. Nguyen T, Nioi P, Pickett CB (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284:13291–13295

    Google Scholar 

  58. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tuder RM, Biswal S (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114:1248–1259

    Google Scholar 

  59. Shureiqi I, Baron JA (2011) Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila) 4:296–298

    Google Scholar 

  60. Kensler TW, Ng D, Carmella SG, Chen M, Jacobson LP, Munoz A, Egner PA, Chen JG, Qian GS, Chen TY et al (2012) Modulation of the metabolism of airborne pollutants by glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. Carcinogenesis 33:101–107

    Google Scholar 

  61. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES et al (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:106–109

    Google Scholar 

  62. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, Winnard PT Jr, Raman V, Ebina M, Nukiwa T et al (2010) Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 31:1833–1843

    Google Scholar 

  63. Sporn MB, Liby KT (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12:564–571

    Google Scholar 

  64. Benowitz NL (1992) Cigarette smoking and nicotine addiction. Med Clin North Am 76:415–437

    Google Scholar 

  65. Zhang JY, Wang Y, Prakash C (2006) Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7:939–948

    Google Scholar 

  66. Dix TA, Marnett LJ (1983) Metabolism of polycyclic aromatic hydrocarbon derivatives to ultimate carcinogens during lipid peroxidation. Science 221:77–79

    Google Scholar 

  67. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S (2002) Point: myeloperoxidase − 463G - > a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 11:1550–1554

    Google Scholar 

  68. Houghton AM (2013) Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13:233–245

    Google Scholar 

  69. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516

    Google Scholar 

  70. Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239

    Google Scholar 

  71. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA et al (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123–127

    Google Scholar 

  72. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048–1051

    Google Scholar 

  73. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110:625–632

    Google Scholar 

  74. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD (1996) Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 93:3942–3946

    Google Scholar 

  75. Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, Glick A, Sheppard D (2003) Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature 422:169–173

    Google Scholar 

  76. Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM, Paquet AC, Erle DJ (2005) A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med 172:1383–1392

    Google Scholar 

  77. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, Stidley C, Melen E, Soderhall C, Hallberg J et al (2009) MMP12, lung function, and COPD in high-risk populations. N Engl J Med 361:2599–2608

    Google Scholar 

  78. Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, Cornelius LA, Shapiro SD (2006) Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 66:6149–6155

    Google Scholar 

  79. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845–6852

    Google Scholar 

  80. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ (2002) Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 26:602–609

    Google Scholar 

  81. Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, Fitzgerald M, Barnes PJ (2002) Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 283:L867–L873

    Google Scholar 

  82. Filippov S, Caras I, Murray R, Matrisian LM, Chapman HA Jr, Shapiro S, Weiss SJ (2003) Matrilysin-dependent elastolysis by human macrophages. J Exp Med 198:925–935

    Google Scholar 

  83. Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, Ijem WG, Deslee G, Moore CH, Jacobs ME et al (2011) The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 183:876–884

    Google Scholar 

  84. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744

    Google Scholar 

  85. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490

    Google Scholar 

  86. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691

    Google Scholar 

  87. Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103:12493–12498

    Google Scholar 

  88. D'Armiento J, Dalal SS, Okada Y, Berg RA, Chada K (1992) Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71:955–961

    Google Scholar 

  89. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Pare PD, Sandford AJ (2002) The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 11:569–576

    Google Scholar 

  90. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765–770

    Google Scholar 

  91. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massague J, Kang Y (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23:1882–1894

    Google Scholar 

  92. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524

    Google Scholar 

  93. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ (2006) A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 20:2673–2686

    Google Scholar 

  94. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I et al (1999) MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:81–92

    Google Scholar 

  95. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392

    Google Scholar 

  96. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–672

    Google Scholar 

  97. Page MJ, Di Cera E (2008) Serine peptidases: classification, structure and function. Cell Mol Life Sci 65:1220–1236

    Google Scholar 

  98. Adkison AM, Raptis SZ, Kelley DG, Pham CT (2002) Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 109:363–371

    Google Scholar 

  99. Davies MJ, Lomas DA (2008) The molecular aetiology of the serpinopathies. Int J Biochem Cell Biol 40:1273–1286

    Google Scholar 

  100. Hedstrom L (2002) Serine protease mechanism and specificity. Chem Rev 102:4501–4524

    Google Scholar 

  101. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA (1977) The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 116:469–475

    Google Scholar 

  102. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A (2003) Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 163:2329–2335

    Google Scholar 

  103. Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, Fallahnejad M, Weinbaum G (1986) Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 78:482–493

    Google Scholar 

  104. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR et al (2010) Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16:219–223

    Google Scholar 

  105. Gregory AD, Hale P, Perlmutter DH, Houghton AM (2012) Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsin G by cancer cells. J Biol Chem 287:35341–35350

    Google Scholar 

  106. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF (2000) Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 106:1311–1319

    Google Scholar 

  107. Aoshiba K, Yokohori N, Nagai A (2003) Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 28:555–562

    Google Scholar 

  108. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM (2005) Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 11:491–498

    Google Scholar 

  109. Mouded M, Egea EE, Brown MJ, Hanlon SM, Houghton AM, Tsai LW, Ingenito EP, Shapiro SD (2009) Epithelial cell apoptosis causes acute lung injury masquerading as emphysema. Am J Respir Cell Mol Biol 41:407–414

    Google Scholar 

  110. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A (2013) Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 4:15

    Google Scholar 

  111. 1980. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93:391–398.

    Google Scholar 

  112. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409

    Google Scholar 

  113. Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK et al (2013) American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 63:107–117

    Google Scholar 

  114. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH (2007) Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:712–719

    Google Scholar 

  115. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789

    Google Scholar 

  116. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386

    Google Scholar 

  117. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861–867

    Google Scholar 

  118. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB et al (2011) Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4:984–993

    Google Scholar 

  119. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT et al (2011) Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 4:793–802

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    A. McGarry Houghton

  2. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Steven D. Shapiro

Authors
  1. A. McGarry Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven D. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. David Geffen School of Medicine at UCLA, Los Angeles, California, USA

    Steven M. Dubinett

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Houghton, A., Shapiro, S. (2015). Inflammation and Lung Cancer: The Relationship to Chronic Obstructive Pulmonary Disease. In: Dubinett, S. (eds) Inflammation and Lung Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2724-1_1

Download citation

Publish with us

Policies and ethics

Search

Navigation